NCT07787273 Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
| NCT ID | NCT07787273 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Hefei Cancer Hospital of the Chinese Academy of Sciences |
| Condition | Locally Advanced Esophageal Squamous Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2026-03-20 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 84 participants in total. It began in 2026-03-20 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.
Eligibility Criteria
Inclusion Criteria: 1. Aged \>= 18 years; 2. Histologically confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 4. Expected overall survival \> 6 months; 5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function. Exclusion Criteria: 1. Active autoimmune disease; 2. Requirement for systemic immunosuppressive therapy; 3. Hypersensitivity to any study drug; 4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection; 5. Pregnant or lactating female.
Contact & Investigator
Hongzhi Wang
STUDY CHAIR
Hefei Cancer Hospital, Chinese Academy of Sciences
Frequently Asked Questions
Who can join the NCT07787273 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Esophageal Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07787273 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07787273 currently recruiting?
Yes, NCT07787273 is actively recruiting participants. Contact the research team at wanghz@hfcas.ac.cn for enrollment information.
Where is the NCT07787273 trial being conducted?
This trial is being conducted at Hefei, China, Hefei, China.
Who is sponsoring the NCT07787273 clinical trial?
NCT07787273 is sponsored by Hefei Cancer Hospital of the Chinese Academy of Sciences. The principal investigator is Hongzhi Wang at Hefei Cancer Hospital, Chinese Academy of Sciences. The trial plans to enroll 84 participants.